Product Information:


RMC-6291 is an orally active and covalent inhibitor of KRASG12C(ON). RMC-6291 forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). RMC-6291 elicits deep and durable suppression on RAS pathway activity in KRASG12C tumor models.

Cat. No.: EX-A7663    Purity: >98%
For research only, Do not use for Human!

SizeUnit Price (US$)StockQuantityOrder
25mgget quoteIn-stock
50mgget quoteIn-stock
100mgget quoteIn-stock
500mgget quoteIn-stock

CAS No.2641998-63-0
Mol Weight1012.2617
Appearancesolid powder
SolubilitySoluble in DMSO
Shelf Life>2 years if stored properly
StoragePowder -20℃ 2 years; In solvent -20℃ 1 month;
ShippingShipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

[1]. Schulze, Christopher J et al. “Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS.” Science (New York, N.Y.) vol. 381,6659 (2023): 794-799.

[2]. Nichols R J, et al. RMC-6291, a next-generation tri-complex KRASG12C (ON) inhibitor, outperforms KRASG12C (OFF) inhibitors in preclinical models of KRASG12C cancers[J]. Cancer Research, 2022, 82(12_Supplement): 3595-3595.

Data SheetData sheet of RMC-6291
CoACoA of RMC-6291
SDSSDS of RMC-6291

KEYWORDS: buy RMC-6291 | RMC-6291 supplier | purchase | cost | manufacturer | order | distributor | buy 2641998-63-0 | 2641998-63-0 supplier